All In Biotech

Drug Trial Radar · NCT01352559

Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype

Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype

Last checked: Nov 19, 2026Latest source record: Dec 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Nov 2001

Primary completion

Mar 2007

Study completion Dec 2018

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 12, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 19 years, up to 89 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether pharmacogenomic study of bioamine transporters and peripheral lymphatic biomarkers(phenotype) predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.

Conditions

  • Depression

Interventions

  • respondersDrug

    Antidepressants administration for 6 weeks under therapeutic dose

  • non-respondersDrug

    Antidepressants administration for 6 weeks under therapeutic dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Antidepressant Response at 6 weeksTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Kangnam, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.